Gynofem Healthcare and Pharmaceuticals
Indore women's-health pharma company incorporated in 2022 with ₹9.9 Cr paid-up capital, quoted at ₹45 per ₹10 share.
Market cap
₹44.64 Cr
0.99 Cr shares
P/E ratio
15.96
Sector average 28
Book value
₹15.85
P/B 2.84
1-year return
+0.00%
52w ₹45 – ₹45
Currently 0% of the way through its 52-week range.
Indicative price history
1Y change
+0.00% ₹45 → ₹45
52-week band in this window: ₹45.00 – ₹45.00. Weekly indicative marks, not exchange-traded prices.
Key highlights
- Incorporated October 2022 in Indore; women's-health formulations.
- Paid-up capital ₹9.92 Cr — about 99 lakh shares of ₹10.
- Dealer quote ₹45 (₹57 on an older page).
About Gynofem
Gynofem Healthcare and Pharmaceuticals Ltd was incorporated in Indore in October 2022 as a public company, succeeding the 2016-vintage Gynofem Healthcare Pvt Ltd. It markets gynaecology and women's-health formulations — hormonal, fertility-support, antenatal and intimate-hygiene products — through a field force covering Madhya Pradesh and neighbouring states, with manufacturing outsourced to third-party plants.
Registry data show authorised capital of ₹10 Cr and paid-up capital of ₹9.92 Cr, giving about 99 lakh shares of ₹10. The board comprises Nishi Kant Joshi, Kartikay Joshi and Anurag Mendhe. No audited revenue figures are visible publicly yet; the estimates below assume a small, growing marketing company.
wwipl.com has quoted the stock between ₹45 and ₹57; the lower figure is used here. At ₹45 the market value is about ₹45 Cr.
Figures preliminary; verify from MCA filings. All profit-and-loss and balance-sheet lines are estimates.
Where the revenue comes from
- Gynaecology and hormonal formulations60%
Prescription products for women's health
- Antenatal and nutritional supplements30%
Iron, calcium, folate and pregnancy nutrition
- Intimate hygiene and OTC10%
Consumer products
Products & services
Gynaecology range
Hormonal, fertility-support and infection-management formulations
Antenatal nutrition
Iron, calcium and folate supplements for pregnancy
What works
- • Focused niche (women's health) with a growing field force in central India.
- • Asset-light model — manufacturing outsourced, capital tied up mainly in receivables and inventory.
- • Recent incorporation means a clean, simple capital structure.
What to watch
- • Less than three years of operating history as a public company; no audited numbers are publicly visible.
- • Dealer quotes vary (₹45–57) and there is almost no secondary-market depth.
- • Dependence on third-party manufacturers and on a regional sales network.
- • Every financial figure on this page is an estimate pending MCA filings.
Compare with peers
| Company | Price | Market cap | P/E | P/B | Rev CAGR |
|---|---|---|---|---|---|
| GynofemThis page | ₹45.00 | ₹44.64 Cr | 15.96 | 2.84 | +33.33% |
| Martin & Harris | ₹959.00 | ₹479.5 Cr | 11.99 | 1.88 | +9.92% |
| Pharmed | ₹820.00 | ₹353.11 Cr | 4.37 | 1.19 | +13.55% |
Latest reported year: FY25 ending 31 Mar 2025.